| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta-Lactamases | 10 | 2018 | 57 | 2.170 |
Why?
|
| Plasmids | 9 | 2019 | 291 | 1.730 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2021 | 153 | 1.160 |
Why?
|
| Bacterial Proteins | 9 | 2018 | 922 | 1.110 |
Why?
|
| Enterobacteriaceae | 6 | 2016 | 22 | 1.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 6 | 2018 | 82 | 0.880 |
Why?
|
| DNA Ligases | 8 | 2006 | 13 | 0.880 |
Why?
|
| Cross Infection | 7 | 2018 | 159 | 0.870 |
Why?
|
| Fast Foods | 1 | 2024 | 5 | 0.860 |
Why?
|
| Enterobacteriaceae Infections | 5 | 2017 | 25 | 0.840 |
Why?
|
| Colistin | 2 | 2021 | 7 | 0.840 |
Why?
|
| Bacteriological Techniques | 5 | 2016 | 40 | 0.830 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 3 | 2018 | 11 | 0.820 |
Why?
|
| Genome, Bacterial | 4 | 2017 | 159 | 0.800 |
Why?
|
| Saliva | 2 | 2021 | 128 | 0.800 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2019 | 52 | 0.730 |
Why?
|
| beta-Lactam Resistance | 4 | 2015 | 12 | 0.720 |
Why?
|
| Sanitary Engineering | 2 | 2018 | 3 | 0.710 |
Why?
|
| Reading | 1 | 2021 | 33 | 0.690 |
Why?
|
| Gene Transfer, Horizontal | 3 | 2019 | 42 | 0.670 |
Why?
|
| Multilocus Sequence Typing | 2 | 2016 | 13 | 0.630 |
Why?
|
| Umbilical Cord | 1 | 2018 | 41 | 0.580 |
Why?
|
| Microbiological Techniques | 2 | 2019 | 25 | 0.560 |
Why?
|
| Klebsiella pneumoniae | 5 | 2019 | 41 | 0.550 |
Why?
|
| Water Microbiology | 1 | 2018 | 16 | 0.550 |
Why?
|
| Molecular Epidemiology | 3 | 2016 | 58 | 0.550 |
Why?
|
| Pandemics | 2 | 2022 | 880 | 0.540 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 590 | 0.540 |
Why?
|
| Bacterial Infections | 4 | 2017 | 185 | 0.540 |
Why?
|
| Fetus | 1 | 2018 | 239 | 0.530 |
Why?
|
| Blood Transfusion | 1 | 2018 | 182 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.520 |
Why?
|
| Infant, Premature | 1 | 2018 | 308 | 0.490 |
Why?
|
| Anti-Bacterial Agents | 10 | 2021 | 847 | 0.490 |
Why?
|
| Staphylococcus aureus | 4 | 2017 | 287 | 0.480 |
Why?
|
| Mass Screening | 1 | 2021 | 710 | 0.470 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 38 | 0.460 |
Why?
|
| Hemolysin Proteins | 2 | 2012 | 34 | 0.460 |
Why?
|
| DNA Helicases | 7 | 2006 | 90 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.460 |
Why?
|
| Infection Control | 1 | 2016 | 132 | 0.450 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 71 | 0.450 |
Why?
|
| Humans | 54 | 2024 | 96105 | 0.450 |
Why?
|
| Achievement | 1 | 2014 | 31 | 0.440 |
Why?
|
| Down Syndrome | 1 | 2014 | 54 | 0.440 |
Why?
|
| Bacterial Toxins | 2 | 2012 | 115 | 0.440 |
Why?
|
| Bacteria | 3 | 2018 | 517 | 0.430 |
Why?
|
| Motor Skills | 1 | 2014 | 80 | 0.430 |
Why?
|
| Specimen Handling | 3 | 2021 | 109 | 0.420 |
Why?
|
| DNA-Binding Proteins | 8 | 2006 | 1267 | 0.410 |
Why?
|
| Yeasts | 1 | 2013 | 51 | 0.410 |
Why?
|
| Self Care | 1 | 2014 | 170 | 0.400 |
Why?
|
| Mycoses | 1 | 2013 | 47 | 0.400 |
Why?
|
| Klebsiella Infections | 3 | 2019 | 32 | 0.390 |
Why?
|
| Child Development | 1 | 2014 | 174 | 0.390 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2012 | 5 | 0.380 |
Why?
|
| DNA Repair | 8 | 2006 | 376 | 0.360 |
Why?
|
| Hemochromatosis | 1 | 2011 | 12 | 0.350 |
Why?
|
| Th17 Cells | 1 | 2012 | 97 | 0.350 |
Why?
|
| Yersinia pestis | 1 | 2011 | 24 | 0.350 |
Why?
|
| Plague | 1 | 2011 | 27 | 0.350 |
Why?
|
| Host-Pathogen Interactions | 2 | 2014 | 241 | 0.340 |
Why?
|
| Escherichia coli | 4 | 2017 | 627 | 0.330 |
Why?
|
| Acinetobacter Infections | 2 | 2016 | 19 | 0.320 |
Why?
|
| Hospitals | 3 | 2018 | 329 | 0.320 |
Why?
|
| Acinetobacter baumannii | 2 | 2016 | 29 | 0.320 |
Why?
|
| Opportunistic Infections | 1 | 2009 | 60 | 0.300 |
Why?
|
| Histoplasmosis | 1 | 2009 | 28 | 0.300 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2008 | 13 | 0.290 |
Why?
|
| Gram-Negative Bacteria | 2 | 2020 | 38 | 0.290 |
Why?
|
| Hematoma | 1 | 2009 | 109 | 0.290 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2019 | 59 | 0.280 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2019 | 202 | 0.270 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 187 | 0.270 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2018 | 22 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 910 | 0.260 |
Why?
|
| Fatal Outcome | 4 | 2019 | 304 | 0.260 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2017 | 14 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 713 | 0.260 |
Why?
|
| Health Personnel | 2 | 2021 | 241 | 0.250 |
Why?
|
| Genetic Therapy | 1 | 2009 | 382 | 0.250 |
Why?
|
| Cell Nucleolus | 1 | 2006 | 25 | 0.250 |
Why?
|
| Carrier State | 2 | 2017 | 40 | 0.250 |
Why?
|
| DNA Ligase ATP | 8 | 2006 | 9 | 0.230 |
Why?
|
| Adenosine Triphosphatases | 1 | 2006 | 156 | 0.230 |
Why?
|
| Disease Outbreaks | 3 | 2016 | 157 | 0.230 |
Why?
|
| Antigens, Nuclear | 6 | 2001 | 28 | 0.230 |
Why?
|
| Ubiquitin | 1 | 2006 | 95 | 0.230 |
Why?
|
| DNA Damage | 3 | 2006 | 392 | 0.220 |
Why?
|
| Bacterial Typing Techniques | 2 | 2014 | 28 | 0.220 |
Why?
|
| Food Handling | 1 | 2024 | 7 | 0.220 |
Why?
|
| Nutritive Value | 1 | 2024 | 6 | 0.220 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 995 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2001 | 465 | 0.210 |
Why?
|
| Nasopharynx | 2 | 2021 | 51 | 0.210 |
Why?
|
| Cytomegalovirus | 1 | 2024 | 89 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2022 | 74 | 0.200 |
Why?
|
| Whole Genome Sequencing | 3 | 2019 | 109 | 0.200 |
Why?
|
| Viral Load | 1 | 2024 | 164 | 0.200 |
Why?
|
| Oxidative Stress | 1 | 2006 | 473 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 155 | 0.200 |
Why?
|
| Intestines | 2 | 2017 | 431 | 0.190 |
Why?
|
| Genes, Bacterial | 3 | 2017 | 199 | 0.180 |
Why?
|
| Epidemiological Monitoring | 3 | 2017 | 43 | 0.180 |
Why?
|
| Polymyxin B | 1 | 2021 | 4 | 0.180 |
Why?
|
| Exome | 1 | 2022 | 141 | 0.180 |
Why?
|
| Medical Informatics Applications | 1 | 2021 | 9 | 0.170 |
Why?
|
| Mouth | 1 | 2021 | 49 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 25 | 0.170 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 43 | 0.170 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 29 | 0.170 |
Why?
|
| Metagenomics | 2 | 2018 | 100 | 0.160 |
Why?
|
| Recombination, Genetic | 3 | 2000 | 444 | 0.160 |
Why?
|
| Fetal Death | 1 | 2000 | 57 | 0.160 |
Why?
|
| Cell Line | 5 | 2006 | 2537 | 0.160 |
Why?
|
| Cholangiocarcinoma | 1 | 2020 | 80 | 0.160 |
Why?
|
| Infant, Newborn | 4 | 2018 | 2614 | 0.160 |
Why?
|
| Time Factors | 6 | 2017 | 5580 | 0.160 |
Why?
|
| Hospices | 1 | 2019 | 8 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2020 | 132 | 0.160 |
Why?
|
| Azabicyclo Compounds | 1 | 2019 | 4 | 0.160 |
Why?
|
| Ceftazidime | 1 | 2019 | 8 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 2039 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2018 | 77 | 0.150 |
Why?
|
| Hospice Care | 1 | 2019 | 43 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 61 | 0.150 |
Why?
|
| Sphingomonas | 1 | 2018 | 4 | 0.150 |
Why?
|
| Drug Contamination | 1 | 2019 | 12 | 0.150 |
Why?
|
| Virus Inactivation | 1 | 2018 | 4 | 0.150 |
Why?
|
| Adenoviridae Infections | 1 | 2019 | 16 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 897 | 0.150 |
Why?
|
| Fetoscopy | 1 | 2018 | 9 | 0.150 |
Why?
|
| Constriction | 1 | 2018 | 27 | 0.150 |
Why?
|
| Disease Reservoirs | 1 | 2018 | 23 | 0.150 |
Why?
|
| Diagnostic Errors | 2 | 2024 | 159 | 0.140 |
Why?
|
| Granuloma | 1 | 2019 | 65 | 0.140 |
Why?
|
| Blood Cells | 1 | 2018 | 34 | 0.140 |
Why?
|
| Disinfection | 1 | 2018 | 16 | 0.140 |
Why?
|
| Acute Pain | 1 | 2018 | 17 | 0.140 |
Why?
|
| Coinfection | 1 | 2018 | 67 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2021 | 137 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2022 | 565 | 0.140 |
Why?
|
| Quality Control | 1 | 2018 | 125 | 0.140 |
Why?
|
| Viruses | 1 | 2018 | 75 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 1 | 2018 | 85 | 0.140 |
Why?
|
| Adenoviridae | 1 | 2019 | 342 | 0.130 |
Why?
|
| Female | 11 | 2022 | 50028 | 0.130 |
Why?
|
| Chaplaincy Service, Hospital | 1 | 2017 | 4 | 0.130 |
Why?
|
| Enterobacter cloacae | 1 | 2017 | 8 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 179 | 0.130 |
Why?
|
| Mice | 16 | 2020 | 12537 | 0.130 |
Why?
|
| Clergy | 1 | 2017 | 24 | 0.130 |
Why?
|
| Caregivers | 2 | 2019 | 185 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 84 | 0.130 |
Why?
|
| Auranofin | 1 | 2016 | 1 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2021 | 372 | 0.130 |
Why?
|
| Hypothermia | 1 | 2016 | 27 | 0.130 |
Why?
|
| Child, Hospitalized | 1 | 2017 | 41 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2019 | 249 | 0.130 |
Why?
|
| Prevalence | 2 | 2018 | 1349 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2018 | 378 | 0.130 |
Why?
|
| Germany | 1 | 2016 | 80 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 209 | 0.120 |
Why?
|
| Spirituality | 1 | 2017 | 87 | 0.120 |
Why?
|
| Neurons | 5 | 2001 | 1653 | 0.120 |
Why?
|
| Body Temperature | 1 | 2016 | 131 | 0.120 |
Why?
|
| Enterococcus faecium | 1 | 2016 | 33 | 0.120 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.120 |
Why?
|
| Aeromonas hydrophila | 1 | 2016 | 1 | 0.120 |
Why?
|
| Nocardia Infections | 1 | 2016 | 4 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 36 | 0.120 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 61 | 0.120 |
Why?
|
| Telemedicine | 1 | 2019 | 229 | 0.120 |
Why?
|
| Nuclear Proteins | 7 | 2004 | 750 | 0.120 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 12 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2016 | 118 | 0.120 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 85 | 0.120 |
Why?
|
| Chronic Pain | 1 | 2018 | 186 | 0.120 |
Why?
|
| Liver | 2 | 2011 | 1238 | 0.120 |
Why?
|
| Yersinia | 1 | 2015 | 2 | 0.110 |
Why?
|
| Virulence Factors | 2 | 2014 | 113 | 0.110 |
Why?
|
| Yersinia Infections | 1 | 2015 | 5 | 0.110 |
Why?
|
| Shigella | 1 | 2015 | 2 | 0.110 |
Why?
|
| Dysentery, Bacillary | 1 | 2015 | 3 | 0.110 |
Why?
|
| Salmonella | 1 | 2015 | 14 | 0.110 |
Why?
|
| Anal Canal | 1 | 2016 | 92 | 0.110 |
Why?
|
| Salmonella Infections | 1 | 2015 | 18 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 197 | 0.110 |
Why?
|
| Male | 12 | 2022 | 45863 | 0.110 |
Why?
|
| Classification | 1 | 2015 | 55 | 0.110 |
Why?
|
| Perioperative Care | 1 | 2016 | 188 | 0.110 |
Why?
|
| Immune Evasion | 1 | 2014 | 37 | 0.110 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 34 | 0.110 |
Why?
|
| Staphylococcal Protein A | 1 | 2014 | 42 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 793 | 0.110 |
Why?
|
| Parents | 1 | 2017 | 307 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 197 | 0.100 |
Why?
|
| Genomics | 2 | 2022 | 857 | 0.100 |
Why?
|
| Neoplasms | 3 | 2019 | 3248 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2013 | 3489 | 0.100 |
Why?
|
| Critical Care | 1 | 2016 | 447 | 0.100 |
Why?
|
| Skin | 1 | 2016 | 605 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2018 | 854 | 0.090 |
Why?
|
| United States | 6 | 2024 | 7768 | 0.090 |
Why?
|
| Animals | 17 | 2020 | 28891 | 0.090 |
Why?
|
| Fibroblasts | 6 | 2001 | 777 | 0.090 |
Why?
|
| Microbiota | 2 | 2016 | 426 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2011 | 11 | 0.090 |
Why?
|
| Translocation, Genetic | 3 | 2001 | 263 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 289 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2018 | 10287 | 0.090 |
Why?
|
| Infant | 2 | 2017 | 3363 | 0.090 |
Why?
|
| Ferritins | 1 | 2011 | 31 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2534 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2017 | 3974 | 0.090 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 99 | 0.090 |
Why?
|
| Autopsy | 1 | 2011 | 129 | 0.090 |
Why?
|
| Mice, Knockout | 8 | 2011 | 2161 | 0.080 |
Why?
|
| DNA, Bacterial | 3 | 2017 | 253 | 0.080 |
Why?
|
| DNA-Activated Protein Kinase | 4 | 2004 | 17 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1805 | 0.080 |
Why?
|
| Research Personnel | 1 | 2011 | 84 | 0.080 |
Why?
|
| Iron | 1 | 2011 | 179 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2011 | 220 | 0.080 |
Why?
|
| Adult | 7 | 2019 | 28721 | 0.080 |
Why?
|
| Pneumonia | 1 | 2011 | 197 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 555 | 0.080 |
Why?
|
| Dependovirus | 1 | 2009 | 37 | 0.080 |
Why?
|
| Retroperitoneal Space | 1 | 2009 | 42 | 0.080 |
Why?
|
| Middle Aged | 7 | 2019 | 28368 | 0.080 |
Why?
|
| Histoplasma | 1 | 2009 | 16 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 2 | 2000 | 111 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1876 | 0.070 |
Why?
|
| Blood | 1 | 2008 | 69 | 0.070 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 1999 | 20 | 0.070 |
Why?
|
| Culture Media | 2 | 2020 | 150 | 0.070 |
Why?
|
| Central Nervous System | 2 | 2000 | 154 | 0.070 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 2 | 1999 | 37 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 191 | 0.070 |
Why?
|
| Cause of Death | 1 | 2009 | 278 | 0.070 |
Why?
|
| Muscles | 1 | 2008 | 193 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2009 | 446 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2019 | 214 | 0.070 |
Why?
|
| Phenotype | 4 | 2022 | 2578 | 0.070 |
Why?
|
| Lymphocytes | 2 | 2000 | 489 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 826 | 0.070 |
Why?
|
| Child | 2 | 2017 | 7625 | 0.060 |
Why?
|
| RecQ Helicases | 1 | 2006 | 8 | 0.060 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2014 | 129 | 0.060 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 30 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1535 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 59 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 3040 | 0.060 |
Why?
|
| Ku Autoantigen | 6 | 2001 | 15 | 0.060 |
Why?
|
| Cell Cycle | 4 | 2000 | 516 | 0.060 |
Why?
|
| Adolescent | 2 | 2017 | 9895 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 314 | 0.060 |
Why?
|
| Lung | 1 | 2012 | 1384 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2591 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2006 | 522 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2014 | 1134 | 0.060 |
Why?
|
| Carbapenems | 2 | 2015 | 12 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1276 | 0.050 |
Why?
|
| Enzyme Stability | 1 | 2004 | 41 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2006 | 623 | 0.050 |
Why?
|
| Gene Rearrangement | 3 | 2000 | 179 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 282 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 422 | 0.050 |
Why?
|
| Genotype | 2 | 2016 | 1881 | 0.050 |
Why?
|
| Apoptosis | 5 | 2001 | 1756 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 147 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 548 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2001 | 107 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2001 | 358 | 0.050 |
Why?
|
| Genes, Lethal | 2 | 2000 | 52 | 0.050 |
Why?
|
| Mutagenesis | 2 | 2001 | 202 | 0.050 |
Why?
|
| Cellular Senescence | 2 | 2000 | 106 | 0.050 |
Why?
|
| Chromosome Aberrations | 2 | 2001 | 393 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 540 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2004 | 1157 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2001 | 143 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2021 | 79 | 0.040 |
Why?
|
| Taste Disorders | 1 | 2021 | 10 | 0.040 |
Why?
|
| Ataxia Telangiectasia | 1 | 2001 | 12 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2001 | 279 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 19 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2001 | 229 | 0.040 |
Why?
|
| Oropharynx | 1 | 2020 | 15 | 0.040 |
Why?
|
| Polyethylene Terephthalates | 1 | 2020 | 19 | 0.040 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 9 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2090 | 0.040 |
Why?
|
| Base Sequence | 1 | 2004 | 2344 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 4671 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 150 | 0.040 |
Why?
|
| Quinine | 1 | 2000 | 7 | 0.040 |
Why?
|
| Babesiosis | 1 | 2000 | 4 | 0.040 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2000 | 18 | 0.040 |
Why?
|
| Clindamycin | 1 | 2000 | 15 | 0.040 |
Why?
|
| Antimalarials | 1 | 2000 | 21 | 0.040 |
Why?
|
| Genome | 2 | 2000 | 407 | 0.040 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1999 | 29 | 0.040 |
Why?
|
| Sarcoma | 1 | 2001 | 225 | 0.040 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1999 | 26 | 0.040 |
Why?
|
| Directed Molecular Evolution | 1 | 2019 | 21 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 326 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2000 | 176 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 107 | 0.040 |
Why?
|
| Hospitals, Federal | 1 | 2018 | 1 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 1999 | 120 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 2860 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 95 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2019 | 132 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 84 | 0.040 |
Why?
|
| Respiratory System | 1 | 2019 | 121 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 1998 | 69 | 0.040 |
Why?
|
| Cell Division | 1 | 2000 | 705 | 0.040 |
Why?
|
| Neonatal Nursing | 1 | 2018 | 2 | 0.040 |
Why?
|
| Water Supply | 1 | 2018 | 66 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 68 | 0.040 |
Why?
|
| Nursing Assessment | 1 | 2018 | 20 | 0.040 |
Why?
|
| Gene Targeting | 1 | 1998 | 78 | 0.040 |
Why?
|
| Internet | 1 | 2021 | 340 | 0.040 |
Why?
|
| Microscopy | 1 | 2019 | 91 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 210 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 157 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 819 | 0.030 |
Why?
|
| Nanopores | 1 | 2017 | 8 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 151 | 0.030 |
Why?
|
| Genes, MDR | 1 | 2017 | 7 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 872 | 0.030 |
Why?
|
| B-Lymphocytes | 3 | 2014 | 771 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2017 | 25 | 0.030 |
Why?
|
| Nucleosides | 1 | 2017 | 23 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 80 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2000 | 683 | 0.030 |
Why?
|
| Software | 1 | 2021 | 698 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 128 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2016 | 21 | 0.030 |
Why?
|
| Heart | 1 | 1999 | 591 | 0.030 |
Why?
|
| Biological Transport | 1 | 2017 | 412 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 5961 | 0.030 |
Why?
|
| Acinetobacter | 1 | 2016 | 4 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 317 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2016 | 52 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1999 | 775 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2019 | 537 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1220 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2014 | 15 | 0.030 |
Why?
|
| Calcium | 1 | 1999 | 1205 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1828 | 0.030 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2014 | 27 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2014 | 110 | 0.030 |
Why?
|
| Germinal Center | 1 | 2014 | 65 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2014 | 333 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2014 | 88 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 360 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 502 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 126 | 0.030 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2013 | 43 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 2013 | 83 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 100 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 299 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 460 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 218 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 116 | 0.020 |
Why?
|
| Data Collection | 1 | 2014 | 381 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2013 | 111 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 411 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 728 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 943 | 0.020 |
Why?
|
| Symbiosis | 1 | 2013 | 134 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2013 | 229 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 706 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 526 | 0.020 |
Why?
|
| ADAM10 Protein | 1 | 2011 | 8 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2011 | 27 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 517 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 4374 | 0.020 |
Why?
|
| Epithelium | 1 | 2011 | 322 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2001 | 2939 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 179 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 615 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2880 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1423 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2001 | 1667 | 0.020 |
Why?
|
| T-Lymphocytes | 3 | 2001 | 1316 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2777 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1429 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2013 | 766 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1063 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 2061 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2418 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 7025 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2001 | 6 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 86 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2001 | 64 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 382 | 0.010 |
Why?
|
| Diencephalon | 1 | 2000 | 6 | 0.010 |
Why?
|
| Babesia | 1 | 2000 | 2 | 0.010 |
Why?
|
| Hematocrit | 1 | 2000 | 69 | 0.010 |
Why?
|
| Antibodies, Protozoan | 1 | 2000 | 46 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 124 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2000 | 91 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 232 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 224 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2000 | 157 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 465 | 0.010 |
Why?
|
| Creatinine | 1 | 2000 | 299 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 301 | 0.010 |
Why?
|
| Genes, Essential | 1 | 1998 | 20 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1998 | 71 | 0.010 |
Why?
|
| Growth | 1 | 1999 | 43 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2000 | 252 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 1998 | 124 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 253 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2001 | 412 | 0.010 |
Why?
|
| Nervous System | 1 | 1999 | 92 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 813 | 0.010 |
Why?
|
| Thymus Neoplasms | 1 | 1997 | 47 | 0.010 |
Why?
|
| Fetal Growth Retardation | 1 | 1997 | 72 | 0.010 |
Why?
|
| Homeostasis | 1 | 1999 | 467 | 0.010 |
Why?
|
| Body Patterning | 1 | 1998 | 217 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 20968 | 0.010 |
Why?
|
| Myocardium | 1 | 1999 | 592 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 1773 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2000 | 615 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1999 | 662 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 1562 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 1999 | 563 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 816 | 0.010 |
Why?
|